We are live on ! Find out more
CRL icon

Charles River Laboratories

407 hedge funds and large institutions have $5.16B invested in Charles River Laboratories in 2018 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 117 increasing their positions, 155 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more call options, than puts

Call options by funds: $18.3M | Put options by funds: $5.82M

141% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 32

11% more funds holding

Funds holding: 366407 (+41)

2.02% less ownership

Funds ownership: 97.11%95.09% (-2%)

18% less capital invested

Capital invested by funds: $6.27B → $5.16B (-$1.11B)

25% less repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 155

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
407
Holders Change
+41
Holders Change %
+11.2%
% of All Funds
9.07%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
77
Increased
117
Reduced
155
Closed
32
Calls
$18.3M
Puts
$5.82M
Net Calls
+$12.5M
Net Calls Change
+$931K
Name Holding Trade Value Shares
Change
Change in
Stake
RE
351
RBC Europe
United Kingdom
$24.9K
FRA
352
Front Row Advisors
California
$24K
PA
353
Parallel Advisors
California
$24K
ER
354
Enlightenment Research
Florida
$23K +$25K +200 New
Pacer Advisors
355
Pacer Advisors
Pennsylvania
$20K -$2.14M -17,098 -99%
Loomis, Sayles & Company
356
Loomis, Sayles & Company
Massachusetts
$20K -$3K -24 -12%
SMFS
357
Squar Milner Financial Services
California
$19K -$876 -7 -4%
Carson Wealth (CWM LLC)
358
Carson Wealth (CWM LLC)
Nebraska
$19K +$13.5K +108 +183%
CAM
359
Cresset Asset Management
Illinois
$19K +$20.9K +167 New
Fuller & Thaler Asset Management
360
Fuller & Thaler Asset Management
California
$18K
GAM
361
Gemmer Asset Management
California
$18K
TAIM
362
TD Ameritrade Investment Management
Nebraska
$17K
CTC
363
Central Trust Company
Missouri
$17K +$2.5K +20 +15%
IA
364
IFP Advisors
Florida
$17K +$8.26K +66 +75%
AIM
365
Advantage Investment Management
Iowa
$17K +$19.3K +154 New
AQA
366
Alpha Quant Advisors
Texas
$16K +$18.2K +145 New
FHA
367
Flagship Harbor Advisors
Massachusetts
$15K
Schroder Investment Management Group
368
Schroder Investment Management Group
United Kingdom
$14.9K +$1.44M +11,531 +10%
MPWT
369
MassMutual Private Wealth & Trust
Connecticut
$14.7K -$3.63K -29 -18%
TF
370
Tompkins Financial
New York
$14K -$9.64K -77 -39%
PCIA
371
Prime Capital Investment Advisors
Kansas
$14K +$15.4K +123 New
PCG
372
Private Capital Group
Connecticut
$13K
EWM
373
Executive Wealth Management
Michigan
$13K +$14.9K +119 New
Northwestern Mutual Wealth Management
374
Northwestern Mutual Wealth Management
Wisconsin
$11K -$12.3K -98 -50%
Macquarie Group
375
Macquarie Group
Australia
$11K +$12.5K +100 New

CRL Hedge Fund Activity: Q4 2018 in Review

407 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2018, worth a combined $5.16B — down 18% from $6.27B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new CRL positions and 32 closed out — a net gain of 45 holders — while 117 added to existing stakes and 155 trimmed.

The largest buyer was Epoch Investment Partners, opening a new position worth an estimated $43.1M. The largest seller was Fidelity International, cutting an estimated $96.6M.

  • 407 institutional investors held Charles River Laboratories (CRL) as of Q4 2018, up from 366 in Q3 2018.
  • Funds reported $5.16B of Charles River Laboratories stock for Q4 2018, down 18% quarter-over-quarter.
  • 77 funds opened new Charles River Laboratories positions in Q4 2018 and 32 closed out, a net change of +45 holders.
  • The largest Charles River Laboratories buyer in Q4 2018 was Epoch Investment Partners, an estimated $43.1M added.
  • The largest Charles River Laboratories seller in Q4 2018 was Fidelity International, an estimated $96.6M sold.

Based on aggregated 13F filings for Q4 2018.